Journal articles on the topic 'Irreversible inhibitor'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Irreversible inhibitor.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Buneeva, O. A., L. N. Aksenova, and A. E. Medvedev. "A Simple Approach for Pilot Analysis of Time-dependent Enzyme Inhibition: Discrimination Between Mechanism-based Inactivation and Tight Binding Inhibitor Behavior." Biomedical Chemistry: Research and Methods 3, no. 1 (2020): e00115. http://dx.doi.org/10.18097/bmcrm00115.
Full textGledhill, L., P. Williams, and B. W. Bycroft. "Irreversible inactivation of β-lactamase I from Bacillus cereus by chlorinated 6-spiroepoxypenicillins." Biochemical Journal 276, no. 3 (June 15, 1991): 801–7. http://dx.doi.org/10.1042/bj2760801.
Full textRožman, Kaja, Evan M. Alexander, Eva Ogorevc, Krištof Bozovičar, Izidor Sosič, Courtney C. Aldrich, and Stanislav Gobec. "Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome." Molecules 25, no. 6 (March 12, 2020): 1305. http://dx.doi.org/10.3390/molecules25061305.
Full textMorgan, Hugh P., Martin J. Walsh, Elizabeth A. Blackburn, Martin A. Wear, Matthew B. Boxer, Min Shen, Henrike Veith, et al. "A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase." Biochemical Journal 448, no. 1 (October 18, 2012): 67–72. http://dx.doi.org/10.1042/bj20121014.
Full textVerdugo, Anael, P. K. Vinod, John J. Tyson, and Bela Novak. "Molecular mechanisms creating bistable switches at cell cycle transitions." Open Biology 3, no. 3 (March 2013): 120179. http://dx.doi.org/10.1098/rsob.120179.
Full textViczjan, Gabor, Tamas Erdei, Ignac Ovari, Nora Lampe, Reka Szekeres, Mariann Bombicz, Barbara Takacs, et al. "A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A1 Adenosine Receptor Antagonist So Far." International Journal of Molecular Sciences 22, no. 18 (September 11, 2021): 9831. http://dx.doi.org/10.3390/ijms22189831.
Full textKondža, Martin, Mirza Bojić, Ivona Tomić, Željan Maleš, Valentina Rezić, and Ivan Ćavar. "Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids." Molecules 26, no. 10 (May 19, 2021): 3018. http://dx.doi.org/10.3390/molecules26103018.
Full textEspín, J. C., and J. Tudela. "Experimental approach to the kinetic study of unstable site-directed irreversible inhibitors: kinetic origin of the apparent positive co-operativity arising from inactivation of trypsin by p-amidinophenylmethanesulphonyl fluoride." Biochemical Journal 299, no. 1 (April 1, 1994): 29–35. http://dx.doi.org/10.1042/bj2990029.
Full textBitonti, A. J., P. J. Casara, P. P. McCann, and P. Bey. "Catalytic irreversible inhibition of bacterial and plant arginine decarboxylase activities by novel substrate and product analogues." Biochemical Journal 242, no. 1 (February 15, 1987): 69–74. http://dx.doi.org/10.1042/bj2420069.
Full textLiyanage, Piyumi Dinusha, Pabudi Weerathunge, Mandeep Singh, Vipul Bansal, and Rajesh Ramanathan. "L-Cysteine as an Irreversible Inhibitor of the Peroxidase-Mimic Catalytic Activity of 2-Dimensional Ni-Based Nanozymes." Nanomaterials 11, no. 5 (May 13, 2021): 1285. http://dx.doi.org/10.3390/nano11051285.
Full textMay, Earl, Daniel Urul, Khanh Huynh, Susan Cornell-Kennon, Venkatesh Nemmara, Zhibing Lu, Samuel Hoare, Michelle Lyles, and Erik Schaefer. "Abstract 2061: A proven activity-based workflow for the identification and characterization of time-dependent kinase inhibitors using a continuous assay format." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2061. http://dx.doi.org/10.1158/1538-7445.am2024-2061.
Full textHan, Chun, Jiahong Ren, Feng Su, Xiaoqin Hu, Mengyao Li, Zhijun Wang, and Lintao Wu. "Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines." Anti-Cancer Agents in Medicinal Chemistry 20, no. 6 (June 14, 2020): 724–33. http://dx.doi.org/10.2174/1871520620666200302113206.
Full textTikhonova, O. V., V. S. Skvortsov, and O. A. Raevsky. "Molecular modeling of acetylcholinesterase interaction with irreversible and reversible organophosphorous inhibitors." Biomeditsinskaya Khimiya 57, no. 1 (January 2011): 61–76. http://dx.doi.org/10.18097/pbmc20115701061.
Full textPoole, R. C., and A. P. Halestrap. "Reversible and irreversible inhibition, by stilbenedisulphonates, of lactate transport into rat erythrocytes. Identification of some new high-affinity inhibitors." Biochemical Journal 275, no. 2 (April 15, 1991): 307–12. http://dx.doi.org/10.1042/bj2750307.
Full textYu, Xiangfan, Simei Qiu, Dongshan Sun, Pei Guo, and Quhuan Li. "Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations." Molecules 27, no. 21 (November 2, 2022): 7451. http://dx.doi.org/10.3390/molecules27217451.
Full textBastlein, C., and G. Burckhardt. "Sensitivity of rat renal luminal and contraluminal sulfate transport systems to DIDS." American Journal of Physiology-Renal Physiology 250, no. 2 (February 1, 1986): F226—F234. http://dx.doi.org/10.1152/ajprenal.1986.250.2.f226.
Full textKETTLE, Anthony J., Craig A. GEDYE, and Christine C. WINTERBOURN. "Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide." Biochemical Journal 321, no. 2 (January 15, 1997): 503–8. http://dx.doi.org/10.1042/bj3210503.
Full textRobak, Ewa, and Tadeusz Robak. "Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives." Journal of Clinical Medicine 11, no. 10 (May 16, 2022): 2807. http://dx.doi.org/10.3390/jcm11102807.
Full textWILLIAMS, CARVELL H., and BRENDA BELSHAW. "An iodinated, irreversible inhibitor of monoamine oxidase." Biochemical Society Transactions 13, no. 2 (April 1, 1985): 469–70. http://dx.doi.org/10.1042/bst0130469.
Full textKindler, Hedy L., and Richard L. Schilsky. "Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase." Expert Opinion on Investigational Drugs 9, no. 7 (July 2000): 1635–49. http://dx.doi.org/10.1517/13543784.9.7.1635.
Full textSchaschke, Norbert, Dominga Deluca, Irmgard Assfalg-Machleidt, Clara Höhneke, Christian P. Sommerhoff, and Werner Machleidt. "Epoxysuccinyl Peptide-Derived Cathepsin B Inhibitors: Modulating Membrane Permeability by Conjugation with the C-Terminal Heptapeptide Segment of Penetratin." Biological Chemistry 383, no. 5 (May 15, 2002): 849–52. http://dx.doi.org/10.1515/bc.2002.090.
Full textTipton, K. F., J. M. McCrodden, and M. B. Youdim. "Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." Biochemical Journal 240, no. 2 (December 1, 1986): 379–83. http://dx.doi.org/10.1042/bj2400379.
Full textGreenspan, M. D., H. G. Bull, J. B. Yudkovitz, D. P. Hanf, and A. W. Alberts. "Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by β-lactone inhibitors and binding of these inhibitors to the enzyme." Biochemical Journal 289, no. 3 (February 1, 1993): 889–95. http://dx.doi.org/10.1042/bj2890889.
Full textRobak, Tadeusz, Magda Witkowska, and Piotr Smolewski. "The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions." Cancers 14, no. 3 (February 2, 2022): 771. http://dx.doi.org/10.3390/cancers14030771.
Full textLaw, Brian, Daniel Lu, Priyanka Somanath, James T. Palmer, Taisei Kinoshita, and Thomas Butler. "Abstract 2665: Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2665. http://dx.doi.org/10.1158/1538-7445.am2022-2665.
Full textBridges, A. J. "The Rationale and Strategy Used to Develop a Series of Highly Potent, Irreversible, Inhibitors of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases." Current Medicinal Chemistry 6, no. 9 (September 1999): 825–43. http://dx.doi.org/10.2174/092986730609220401151141.
Full textHashimoto, Yoshitami, and Hirofumi Tanaka. "Mre11 exonuclease activity promotes irreversible mitotic progression under replication stress." Life Science Alliance 5, no. 6 (March 15, 2022): e202101249. http://dx.doi.org/10.26508/lsa.202101249.
Full textNakatani, Toshiyuki, Ken Uda, Takeshi Yamaura, Masaru Takasaki, Akimi Akashi, Fangli Chen, Yuichi Ishikawa, et al. "Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations." Blood 126, no. 23 (December 3, 2015): 1353. http://dx.doi.org/10.1182/blood.v126.23.1353.1353.
Full textBoudier, C., and J. G. Bieth. "Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor." Biochemical Journal 303, no. 1 (October 1, 1994): 61–68. http://dx.doi.org/10.1042/bj3030061.
Full textLombardi, Paolo. "The Irreversible Inhibition of Aromatase (Oestrogen Synthetase) by Steroidal Compounds." Current Pharmaceutical Design 1, no. 1 (June 1995): 23–50. http://dx.doi.org/10.2174/1381612801666220524190226.
Full textGantt, Soren M., Joon Mo Myung, Marcelo R. S. Briones, Wei Dong Li, E. J. Corey, Satoshi Omura, Victor Nussenzweig, and Photini Sinnis. "Proteasome Inhibitors Block Development ofPlasmodium spp." Antimicrobial Agents and Chemotherapy 42, no. 10 (October 1, 1998): 2731–38. http://dx.doi.org/10.1128/aac.42.10.2731.
Full textZeng, Qingbei, Anilkumar G. Nair, Stuart B. Rosenblum, Hsueh-Cheng Huang, Charles A. Lesburg, Yueheng Jiang, Oleg Selyutin, et al. "Discovery of an irreversible HCV NS5B polymerase inhibitor." Bioorganic & Medicinal Chemistry Letters 23, no. 24 (December 2013): 6585–87. http://dx.doi.org/10.1016/j.bmcl.2013.10.060.
Full textLawyer, Arthur L., Sarita R. Kelley, and Judith I. Allen. "Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity." Zeitschrift für Naturforschung C 42, no. 6 (June 1, 1987): 834–36. http://dx.doi.org/10.1515/znc-1987-0633.
Full textLawyer, Arthur L., Sarita R. Kelley, and Judith I. Allen. "Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity." Zeitschrift für Naturforschung C 42, no. 7-8 (August 1, 1987): 834–36. http://dx.doi.org/10.1515/znc-1987-7-816.
Full textBarrand, M. A., and B. A. Callingham. "The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme." Biochemical Journal 232, no. 2 (December 1, 1985): 415–23. http://dx.doi.org/10.1042/bj2320415.
Full textMaryška, Michal, Lucie Svobodová, Wim Dehaen, Martina Hrabinová, Michaela Rumlová, Ondřej Soukup, and Martin Kuchař. "Heterocyclic Cathinones as Inhibitors of Kynurenine Aminotransferase II—Design, Synthesis, and Evaluation." Pharmaceuticals 14, no. 12 (December 10, 2021): 1291. http://dx.doi.org/10.3390/ph14121291.
Full textZhang, Datong, He Gong, and Fancui Meng. "Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases." Molecules 26, no. 16 (August 13, 2021): 4907. http://dx.doi.org/10.3390/molecules26164907.
Full textHopkins, Michael, John J. Tyson, and Béla Novák. "Cell-cycle transitions: a common role for stoichiometric inhibitors." Molecular Biology of the Cell 28, no. 23 (November 7, 2017): 3437–46. http://dx.doi.org/10.1091/mbc.e17-06-0349.
Full textLee, Eun, Hyewon Cho, Da Kyung Lee, JuHyun Ha, Byeong Jo Choi, Ji Hye Jeong, Jae-Ha Ryu, Jong Soon Kang, and Raok Jeon. "Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase." International Journal of Molecular Sciences 21, no. 21 (October 28, 2020): 8006. http://dx.doi.org/10.3390/ijms21218006.
Full textBrullo, Chiara, Carla Villa, Bruno Tasso, Eleonora Russo, and Andrea Spallarossa. "Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective." International Journal of Molecular Sciences 22, no. 14 (July 16, 2021): 7641. http://dx.doi.org/10.3390/ijms22147641.
Full textHe, Ran, Kyoungsook Park, Hongyi Cai, Arun Kapoor, Michael Forman, Bryan Mott, Gary H. Posner, and Ravit Arav-Boger. "Artemisinin-Derived Dimer Diphenyl Phosphate Is an Irreversible Inhibitor of Human Cytomegalovirus Replication." Antimicrobial Agents and Chemotherapy 56, no. 7 (April 30, 2012): 3508–15. http://dx.doi.org/10.1128/aac.00519-12.
Full textPenning, T. M. "Irreversible inhibition of Δ5-3-oxosteroid isomerase by 2-substituted progesterones." Biochemical Journal 226, no. 2 (March 1, 1985): 469–76. http://dx.doi.org/10.1042/bj2260469.
Full textPark, Jong-Hyun, Yeon Ha Ju, Ji Won Choi, Hyo Jung Song, Bo Ko Jang, Junsung Woo, Heejung Chun, et al. "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease." Science Advances 5, no. 3 (March 2019): eaav0316. http://dx.doi.org/10.1126/sciadv.aav0316.
Full textSteverding, Dietmar. "On the Reversible and Irreversible Inhibition of Rhodesain by Curcumin." Molecules 25, no. 1 (December 30, 2019): 143. http://dx.doi.org/10.3390/molecules25010143.
Full textLighezan, Rodica, Adrian Sturza, Oana M. Duicu, Raluca A. Ceausu, Adrian Vaduva, Marian Gaspar, Horea Feier, et al. "Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease." Canadian Journal of Physiology and Pharmacology 94, no. 10 (October 2016): 1040–47. http://dx.doi.org/10.1139/cjpp-2015-0580.
Full textSchröder, Martin, Panagis Filippakopoulos, Martin P. Schwalm, Carla A. Ferrer, David H. Drewry, Stefan Knapp, and Apirat Chaikuad. "Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3." International Journal of Molecular Sciences 21, no. 21 (October 26, 2020): 7953. http://dx.doi.org/10.3390/ijms21217953.
Full textHarris, Christopher M., Sage E. Foley, Eric R. Goedken, Mark Michalak, Sara Murdock, and Noel S. Wilson. "Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase." SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, no. 10 (July 10, 2018): 1040–50. http://dx.doi.org/10.1177/2472555218787445.
Full textKuhn, Deborah J., Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fred W. van Leeuwen, and Robert Z. Orlowski. "The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance." Blood 108, no. 11 (November 16, 2006): 3461. http://dx.doi.org/10.1182/blood.v108.11.3461.3461.
Full textChung, Vincent, Ling Wang, Margaret S. Fletcher, Erminia Massarelli, Karen L. Reckamp, Mihaela C. Cristea, Nikeeta Prajapati, et al. "First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): TPS3146. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3146.
Full textLiclican, Albert, Weimei Xing, Loredana Serafini, Ting Wang, Kathy Brendza, Justin Lutz, Adrian S. Ray, Brian Schultz, Roman Sakowicz, and Joy Y. Feng. "Biochemical Characterization of GS-4059 As a Potent and Selective Covalent Irreversible Inhibitor of Bruton's Tyrosine Kinase." Blood 128, no. 22 (December 2, 2016): 1594. http://dx.doi.org/10.1182/blood.v128.22.1594.1594.
Full text